Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marie Maitre

Physician Assistant Dallas, TX Physician Assistant

NPI 1295735900 CMS profile 10548432

5201 Harry Hines Blvd, Medical Staff Services, Dallas, TX 75235

Open in the dashboard

General payments

$9,664

42 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marie Maitre of Dallas, TX is reported in the CMS Open Payments database as having received $9,664 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 2
2023 General $3,676 3
2022 General $3,769 31
2021 General $1,945 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marie Maitre
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Marie Maitre were reported at $273. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Marie Maitre Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,945 $132 $37–$438 $132
2022 $3,769 $155 $48–$522 $149
2023 $3,676 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $273 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Scientific Affairs, LLC $4,445 10 payments
  2. Pfizer Inc. $1,440 1 payment
  3. Lilly USA, LLC $1,219 2 payments
  4. Janssen Biotech, Inc. $1,084 7 payments
  5. Amgen Inc. $504 4 payments
  6. GlaxoSmithKline, LLC. $323 11 payments
  7. AbbVie, Inc. $168 2 payments
  8. E.R. Squibb & Sons, L.L.C. $125 1 payment
  9. Aurinia Pharma U.S., Inc. $121 1 payment
  10. Genzyme Corporation $92 1 payment
  11. Other $143 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,600 2 payments
  2. Consulting Fee $2,175 2 payments
  3. Food and Beverage $2,133 36 payments
  4. Honoraria $1,440 1 payment
  5. Travel and Lodging $315 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $5,528 17 payments
  2. SIMPONI ARIA $5,465 15 payments
  3. STELARA $4,417 9 payments
  4. XELJANZ $1,440 1 payment
  5. TAVNEOS $273 2 payments
  6. BENLYSTA $247 10 payments
  7. Enbrel $230 2 payments
  8. RINVOQ $168 2 payments
  9. ORENCIA $125 1 payment
  10. LUPKYNIS $121 1 payment
  11. Other $329 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

712

Median for Physician Assistant: 241

Drug cost

$1,257,571

Median for Physician Assistant: $4,110

Branded share of claims

40.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 75 $563,415
Humira Adalimumab Brand 70 $499,838
Enbrel Sureclick Etanercept Brand 15 $109,153
Orencia Abatacept Brand 12 $64,799
Hydroxychloroquine Sulfate Generic 76 $3,963
Leflunomide Generic 62 $3,938
Azathioprine Generic 28 $2,551
Cevimeline Hcl Generic 14 $2,510
Mycophenolate Mofetil Generic 16 $2,319
Methotrexate Methotrexate Sodium Brand 100 $1,713

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$4,951

Medicare's payments for the services billed

Medicare patients

71

Average age 66

Services billed

125

51 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Osteoporosis 31%
Chronic kidney disease 28%
Heart failure 24%
Ischemic heart disease 23%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record